US equities |
SPCX $167.11 ▲+5.13% NVDA $237.11 ▲+1.35% MU $1,064.39 ▼-0.98% TSLA $377.92 ▲+1.98% MSFT $527.19 ▲+1.87% SNDK $1,714.83 ▼-0.30% INTC $116.63 ▼-2.26% META $745.92 ▲+2.45%
FinancialContent

Articles published by Jade Biosciences

News headline image
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences to Participate in Upcoming Conferences
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences Announces Pricing of Public Offering of Common Stock
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences Announces Proposed Underwritten Public Offering
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences to Participate in Upcoming Conferences
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences Announces $45 Million Private Placement
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences to Participate in Upcoming Conferences
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences Announces $135 Million Private Placement
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences to Participate in Upcoming Conferences
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences to Participate in Two Upcoming Investor Conferences
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences Appoints Brad Dahms as Chief Financial Officer
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO
News headline image
Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy
From Jade Biosciences
Via GlobeNewswire
Tickers JBIO